Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Colorectal Neoplasms 42Colonic Neoplasms 14Rectal Neoplasms 13Neoplasms 12Neoplasm Metastasis 12Head and Neck Neoplasms 6Esophageal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Carcinoma, Squamous Cell 4Breast Neoplasms 4Recurrence 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Adenocarcinoma Of Esophagus 3Triple Negative Breast Neoplasms 2Gastrointestinal Neoplasms 2Cholangiocarcinoma 2Carcinoma 2Biliary Tract Neoplasms 2Urinary Bladder Neoplasms 1Solid Tumors 1Ovarian Neoplasms 1Inflammatory Breast Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Exanthema 1

Interventions

Temozolomide 115Bevacizumab 72Radiotherapy 52Radiation 23Erlotinib Hydrochloride 13Lomustine 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Vorinostat 10Nivolumab 10Surgical Procedures, Operative 9Irinotecan 9Sorafenib 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 7Immunoglobulin G 7Everolimus 7Drug Therapy 7Disulfides 7Radiosurgery 6Granulocyte-Macrophage Colony-Stimulating Factor 6Carmustine 6antineoplaston AS 2-1 5antineoplaston A10 5Sirolimus 5Cilengitide 5veliparib 4veledimex 4temsirolimus 4selinexor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Glioblastoma × Panitumumab × Clear all
NCT01017653 2013-09-04

Panitumumab and Irinotecan for Malignant Gliomas

Duke University

Phase 2 Terminated
16 enrolled 9 charts
CNSSarcoma

Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡